Animal models of Parkinson's disease: An updated overview

Revue Neurologique

Volumn 171, Issue 11, 2015, Pages 750-761

  Gubellini, P ^a   Kachidian, P ^a  

^a AIX MARSEILLE UNIVERSITÉ   (France)

Author keywords

Dopamine; Lewy bodies; Neurodegeneration; Nigrostriatal; Progressive disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; AMPHETAMINE DERIVATIVE; DJ 1 PROTEIN; LEUCINE RICH REPEAT KINASE 2; MANEB; METHAMPHETAMINE; MITOCHONDRIAL TRANSCRIPTION FACTOR A; NEUROTOXIN; OXIDOPAMINE; PARAQUAT; PARKIN; ROTENONE;

AUTOSOMAL DOMINANT INHERITANCE; CHEMICAL STRUCTURE; GENETIC MODEL; HEREDITY; LIPID PEROXIDATION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; POINT MUTATION; REVIEW; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; GENETICS; HUMAN; INTOXICATION; PATHOPHYSIOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MPTP POISONING; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY;

EID: 84947128001     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurol.2015.07.011     Document Type: Review

References (154)

1. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008;79(4):368-76.
2. Olanow CW. The pathogenesis of cell death in Parkinson's disease. Mov Disord 2007;22(Suppl. 17):S335-42.
3. Chaudhuri KR, Odin P, Antonini A, Martinez-Martin P. Parkinson's disease: the non-motor issues. Parkinsonism Relat Disord 2011;17(10):717-23.
4. Brichta L, Greengard P, Flajolet M. Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems. Trends Neurosci 2013;36(9):543-54.
5. von Campenhausen S, Bornschein B, Wick R, Botzel K, Sampaio C, Poewe W, et al. Prevalence and incidence of Parkinson's disease in Europe. Eur Neuropsychopharmacol 2005;15(4):473-90.
6. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006;5(6):525-35.
7. Lindgren P. Economic evidence in Parkinson's disease: a review. Eur J Health Econ 2004;5(Suppl. 1):S63-6.
8. Schapira AH, Jenner P. Etiology and pathogenesis of Parkinson's disease. Mov Disord 2011;26(6):1049-55.
9. Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003;302(5646):819-22.
10. Gubellini P, Picconi B, Di FM, Calabresi P. Downstream mechanisms triggered by mitochondrial dysfunction in the basal ganglia: from experimental models to neurodegenerative diseases. Biochim Biophys Acta 2010;1802(1):151-61.
11. Gasser T, Hardy J, Mizuno Y. Milestones in PD genetics. Mov Disord 2011;26(6):1042-8.
12. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003;39(6):889-909.
13. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16(3):448-58.
14. Chase TN. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology 1998;50(5 Suppl. 5):S17-25.
15. Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology 2009;72(21 Suppl. 4):S1-36.
16. Benabid AL, Koudsie A, Benazzouz A, Piallat B, Krack P, Limousin-Dowsey P, et al. Deep brain stimulation for Parkinson's disease. Adv Neurol 2001;86:405-12.
17. Benabid AL, Chabardes S, Mitrofanis J, Pollak P. Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease. Lancet Neurol 2009;8(1):67-81.
18. Spieles-Engemann AL, Collier TJ, Sortwell CE. A functionally relevant and long-term model of deep brain stimulation of the rat subthalamic nucleus: advantages and considerations. Eur J Neurosci 2010;32(7):1092-9.
19. Gubellini P, Salin P, Kerkerian-Le GL, Baunez C. Deep brain stimulation in neurological diseases and experimental models: from molecule to complex behavior. Prog Neurobiol 2009;89(1):79-123.
20. Rosa M, Giannicola G, Marceglia S, Fumagalli M, Barbieri S, Priori A. Neurophysiology of deep brain stimulation. Int Rev Neurobiol 2012;107:23-55.
21. Karas PJ, Mikell CB, Christian E, Liker MA, Sheth SA. Deep brain stimulation: a mechanistic and clinical update. Neurosurg Focus 2013;35(5):E1.
22. Smith Y, Wichmann T, Factor SA, DeLong MR. Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa. Neuropsychopharmacology 2012;37(1):213-46.
23. Schapira AH, Olanow CW, Greenamyre JT, Bezard E. Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. Lancet 2014;384(9942):545-55.
24. Buttery PC, Barker RA. Treating Parkinson's disease in the 21st century: can stem cell transplantation compete? J Comp Neurol 2014;522(12):2802-16.
25. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 1990;54(3):823-7.
26. Ungerstedt U. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 1968;5(1):107-10.
27. Sachs C, Jonsson G. Mechanisms of action of 6-hydroxydopamine. Biochem Pharmacol 1975;24(1):1-8.
28. Porter CC, Totaro JA, Stone CA. Effect of 6-hydroxydopamine and some other compounds on the concentration of norepinephrine in the hearts of mice. J Pharmacol Exp Ther 1963;140:308-16.
29. Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, Sadoul R, et al. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 2001;65(2):135-72.
30. Gubellini P, Eusebio A, Oueslati A, Melon C, Kerkerian-Le GL, Salin P. Chronic high-frequency stimulation of the subthalamic nucleus and L-DOPA treatment in experimental parkinsonism: effects on motor behaviour and striatal glutamate transmission. Eur J Neurosci 2006;24(6):1802-14.
31. Ungerstedt U, Arbuthnott GW. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 1970;24(3):485-93.
32. Cenci MA, Whishaw IQ, Schallert T. Animal models of neurological deficits: how relevant is the rat? Nat Rev Neurosci 2002;3(7):574-9.
33. Amalric M, Koob GF. Depletion of dopamine in the caudate nucleus but not in nucleus accumbens impairs reactiontime performance in rats. J Neurosci 1987;7(7):2129-34.
34. Gauntlett-Gilbert J, Brown VJ. Reaction time deficits and Parkinson's disease. Neurosci Biobehav Rev 1998;22(6):865-81.
35. Bonito-Oliva A, Masini D, Fisone G. A mouse model of non-motor symptoms in Parkinson's disease: focus on pharmacological interventions targeting affective dysfunctions. Front Behav Neurosci 2014;8:290.
36. Schwarting RK, Huston JP. Unilateral 6-hydroxydopamine lesions of mesostriatal dopamine neurons and their physiological sequelae. Prog Neurobiol 1996;49(3):215-66.
37. Calabresi P, Mercuri NB, Sancesario G, Bernardi G. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease. Brain 1993;116(Pt 2):433-52.
38. Gubellini P, Picconi B, Bari M, Battista N, Calabresi P, Centonze D, et al. Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J Neurosci 2002;22(16):6900-7.
39. Tseng KY, Kasanetz F, Kargieman L, Riquelme LA, Murer MG. Cortical slow oscillatory activity is reflected in the membrane potential and spike trains of striatal neurons in rats with chronic nigrostriatal lesions. J Neurosci 2001;21(16):6430-9.
40. Calabresi P, Centonze D, Bernardi G. Electrophysiology of dopamine in normal and denervated striatal neurons. Trends Neurosci 2000;23(10 Suppl.):S57-63.
41. Paillé V, Picconi B, Bagetta V, Ghiglieri V, Sgobio C, Di Filippo M, et al. Distinct levels of dopamine denervation differentially alter striatal synaptic plasticity and NMDA receptor subunit composition. J Neurosci 2010;30(42):14182-93.
42. Maccarrone M, Gubellini P, Bari M, Picconi B, Battista N, Centonze D, et al. Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. J Neurochem 2003;85(4):1018-25.
43. Picconi B, Centonze D, Hakansson K, Bernardi G, Greengard P, Fisone G, et al. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 2003;6(5):501-6.
44. Oueslati A, Sgambato-Faure V, Melon C, Kachidian P, Gubellini P, Amri M, et al. High-frequency stimulation of the subthalamic nucleus potentiates L-DOPA-induced neurochemical changes in the striatum in a rat model of Parkinson's disease. J Neurosci 2007;27(9):2377-86.
45. Amalric M. Targeting metabotropic glutamate receptors (mGluRs) in Parkinson's disease. Curr Opin Pharmacol 2015;20:29-34.
46. Delaville C, Chetrit J, Abdallah K, Morin S, Cardoit L, De DP, et al. Emerging dysfunctions consequent to combined monoaminergic depletions in Parkinsonism. Neurobiol Dis 2012;45(2):763-73.
47. Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 1985;35(7):949-56.
48. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219(4587):979-80.
49. Przedborski S, Vila M. The 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease. Ann N Y Acad Sci 2003;991:189-98.
50. Kitahama K, Maeda T, Denney RM, Jouvet M. Monoamine oxidase: distribution in the cat brain studied by enzymeand immunohistochemistry: recent progress. Prog Neurobiol 1994;42(1):53-78.
51. Jahng JW, Houpt TA, Wessel TC, Chen K, Shih JC, Joh TH. Localization of monoamine oxidase A and B mRNA in the rat brain by in situ hybridization. Synapse 1997;25(1):30-6.
52. Vitalis T, Fouquet C, Alvarez C, Seif I, Price D, Gaspar P, et al. Developmental expression of monoamine oxidases A and B in the central and peripheral nervous systems of the mouse. J Comp Neurol 2002;442(4):331-47.
53. Trevor AJ, Castagnoli N, Singer TP. The formation of reactive intermediates in the MAO-catalyzed oxidation of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP). Toxicology 1988;49 (2-3):513-9.
54. Singer TP, Ramsay RR, McKeown K, Trevor A, Castagnoli Jr NE. Mechanism of the neurotoxicity of 1-methyl-4-phenylpyridinium (MPP+), the toxic bioactivation product of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Toxicology 1988;49(1):17-23.
55. Nicklas WJ, Vyas I, Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci 1985;36(26):2503-8.
56. Ramsay RR, Singer TP. Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. J Biol Chem 1986;261(17):7585-7.
57. Meredith GE, Totterdell S, Potashkin JA, Surmeier DJ, Modeling PD. pathogenesis in mice: advantages of a chronic MPTP protocol. Parkinsonism Relat Disord 2008;14(Suppl. 2):S112-5.
58. Chiueh CC, Markey SP, Burns RS, Johannessen JN, Jacobowitz DM, Kopin IJ. Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rat, guinea pig, and monkey. Psychopharmacol Bull 1984;20(3):548-53.
59. Meredith GE, Kang UJ. Behavioral models of Parkinson's disease in rodents: a new look at an old problem. Mov Disord 2006;21(10):1595-606.
60. Smeyne RJ, Jackson-Lewis V. The MPTP model of Parkinson's disease. Brain Res Mol Brain Res 2005;134(1):57-66.
61. Forno LS, DeLanney LE, Irwin I, Langston JW. Similarities and differences between MPTP-induced parkinsonsim and Parkinson's disease. Neuropathologic considerations. Adv Neurol 1993;60:600-8.
62. Meredith GE, Totterdell S, Petroske E, Santa CK, Callison Jr RC, Lau YS. Lysosomal malfunction accompanies alphasynuclein aggregation in a progressive mouse model of Parkinson's disease. Brain Res 2002;956(1):156-65.
63. Fornai F, Schluter OM, Lenzi P, Gesi M, Ruffoli R, Ferrucci M, et al. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc Natl Acad Sci USA 2005;102(9):3413-8.
64. Bergman H, Wichmann T, Karmon B, DeLong MR. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J Neurophysiol 1994;72(2):507-20.
65. Bezard E, Boraud T, Bioulac B, Gross CE. Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms. Eur J Neurosci 1999;11(6):2167-70.
66. Meissner W, Leblois A, Hansel D, Bioulac B, Gross CE, Benazzouz A, et al. Subthalamic high frequency stimulation resets subthalamic firing and reduces abnormal oscillations. Brain 2005;128(Pt 10):2372-82.
67. Shimizu K, Ohtaki K, Matsubara K, Aoyama K, Uezono T, Saito O, et al. Carrier-mediated processes in blood-brain barrier penetration and neural uptake of paraquat. Brain Res 2001;906(1-2):135-42.
68. Day BJ, Patel M, Calavetta L, Chang LY, Stamler JS. A mechanism of paraquat toxicity involving nitric oxide synthase. Proc Natl Acad Sci USA 1999;96(22):12760-5.
69. Rappold PM, Cui M, Chesser AS, Tibbett J, Grima JC, Duan L, et al. Paraquat neurotoxicity is mediated by the dopamine transporter and organic cation transporter-3. Proc Natl Acad Sci USA 2011;108(51):20766-71.
70. Czerniczyniec A, Karadayian AG, Bustamante J, Cutrera RA, Lores-Arnaiz S. Paraquat induces behavioral changes and cortical and striatal mitochondrial dysfunction. Free Radic Biol Med 2011;51(7):1428-36.
71. Cocheme HM, Murphy MP. Complex I is the major site of mitochondrial superoxide production by paraquat. J Biol Chem 2008;283(4):1786-98.
72. Vaccari A, Saba PL, Ruiu S, Collu M, Devoto P. Disulfiram and diethyldithiocarbamate intoxication affects the storage and release of striatal dopamine. Toxicol Appl Pharmacol 1996;139(1):102-8.
73. Dinis-Oliveira RJ, Remiao F, Carmo H, Duarte JA, Navarro AS, Bastos ML, et al. Paraquat exposure as an etiological factor of Parkinson's disease. Neurotoxicology 2006;27(6):1110-22.
74. Freire C, Koifman S. Pesticide exposure and Parkinson's disease: epidemiological evidence of association. Neurotoxicology 2012;33(5):947-71.
75. Ossowska K, Wardas J, Smialowska M, Kuter K, Lenda T, Wieronska JM, et al. A slowly developing dysfunction of dopaminergic nigrostriatal neurons induced by long-term paraquat administration in rats: an animal model of preclinical stages of Parkinson's disease? Eur J Neurosci 2005;22(6):1294-304.
76. Ossowska K, Smialowska M, Kuter K, Wieronska J, Zieba B, Wardas J, et al. Degeneration of dopaminergic mesocortical neurons and activation of compensatory processes induced by a long-term paraquat administration in rats: implications for Parkinson's disease. Neuroscience 2006;141(4):2155-65.
77. Brooks AI, Chadwick CA, Gelbard HA, Cory-Slechta DA, Federoff HJ. Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. Brain Res 1999;823(1-2):1-10.
78. McCormack AL, Thiruchelvam M, Manning-Bog AB, Thiffault C, Langston JW, Cory-Slechta DA, et al. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis 2002;10(2):119-27.
79. Thiruchelvam M, McCormack A, Richfield EK, Baggs RB, Tank AW, Di Monte DA, et al. Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype. Eur J Neurosci 2003;18(3):589-600.
80. Takahashi RN, Rogerio R, Zanin M. Maneb enhances MPTP neurotoxicity in mice. Res Commun Chem Pathol Pharmacol 1989;66(1):167-70.
81. Bastias-Candia S, Di BM, D'Addario C, Candeletti S, Romualdi P. Combined exposure to agriculture pesticides, paraquat and maneb, induces alterations in the N/OFQNOPr and PDYN/KOPr systems in rats: relevance to sporadic Parkinson's disease. Environ Toxicol 2013.
82. Manning-Bog AB, McCormack AL, Li J, Uversky VN, Fink AL, Di Monte DA. The herbicide paraquat causes upregulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J Biol Chem 2002;277(3):1641-4.
83. Miller GW. Paraquat: the red herring of Parkinson's disease research. Toxicol Sci 2007;100(1):1-2.
84. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000;3(12):1301-6.
85. Greenamyre JT, Betarbet R, Sherer TB. The rotenone model of Parkinson's disease: genes, environment and mitochondria. Parkinsonism Relat Disord 2003;9(Suppl. 2):S59-64.
86. Cannon JR, Tapias V, Na HM, Honick AS, Drolet RE, Greenamyre JT. A highly reproducible rotenone model of Parkinson's disease. Neurobiol Dis 2009;34(2):279-90.
87. Fleming SM, Zhu C, Fernagut PO, Mehta A, DiCarlo CD, Seaman RL, et al. Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone. Exp Neurol 2004;187(2):418-29.
88. Pan-Montojo F, Anichtchik O, Dening Y, Knels L, Pursche S, Jung R, et al. Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS One 2010;5(1):e8762.
89. Xiong N, Huang J, Zhang Z, Zhang Z, Xiong J, Liu X, et al. Stereotaxical infusion of rotenone: a reliable rodent model for Parkinson's disease. PLoS One 2009;4(11):e 7878.
90. Greenamyre JT, Cannon JR, Drolet R, Mastroberardino PG. Lessons from the rotenone model of Parkinson's disease. Trends Pharmacol Sci 2010;31(4):141-2.
91. Hawkes CH, Del TK, Braak H. Parkinson's disease: the dual hit theory revisited. Ann N Y Acad Sci 2009;1170: 615-622.
92. Wagner GC, Seiden LS, Schuster CR. Methamphetamine-induced changes in brain catecholamines in rats and guinea pigs. Drug Alcohol Depend 1979;4(5):435-8.
93. Trulson ME, Cannon MS, Faegg TS, Raese JD. Effects of chronic methamphetamine on the nigral-striatal dopamine system in rat brain: tyrosine hydroxylase immunochemistry and quantitative light microscopic studies. Brain Res Bull 1985;15(6):569-77.
94. Morrow BA, Roth RH, Redmond DE, Elsworth JD. Impact of methamphetamine on dopamine neurons in primates is dependent on age: implications for development of Parkinson's disease. Neuroscience 2011;189:277-85.
95. Capela JP, Carmo H, Remiao F, Bastos ML, Meisel A, Carvalho F. Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Mol Neurobiol 2009;39(3):210-71.
96. Granado N, O'Shea E, Bove J, Vila M, Colado MI, Moratalla R. Persistent MDMA-induced dopaminergic neurotoxicity in the striatum and substantia nigra of mice. J Neurochem 2008;107(4):1102-12.
97. Costa G, Frau L, Wardas J, Pinna A, Plumitallo A, Morelli M. MPTP-induced dopamine neuron degeneration and glia activation is potentiated in MDMA-pretreated mice. Mov Disord 2013;28(14):1957-65.
98. Beaudoin-Gobert M, Epinat J, Metereau E, Duperrier S, Neumane S, Ballanger B, et al. Behavioural impact of a double dopaminergic and serotonergic lesion in the non-human primate. Brain 2015 [Epub ahead of print].
99. Verstraeten A, Theuns J, Van BC. Progress in unraveling the genetic etiology of Parkinson disease in a genomic era. Trends Genet 2015;31(3):140-9.
100. Fujioka S, Wszolek ZK. Update on genetics of parkinsonism. Neurodegener Dis 2012;10(1-4):257-60.
101. Klein C, Westenberger A. Genetics of Parkinson's disease. Cold Spring Harb Perspect Med 2012;2(1):a008888.
102. Antony PM, Diederich NJ, Balling R. Parkinson's disease mouse models in translational research. Mamm Genome 2011;22(7-8):401-19.
103. Dawson TM, Ko HS, Dawson VL. Genetic animal models of Parkinson's disease. Neuron 2010;66(5):646-61.
104. Kitada T, Tong Y, Gautier CA, Shen J. Absence of nigral degeneration in aged parkin/DJ-1/PINK1 triple knockout mice. J Neurochem 2009;111(3):696-702.
105. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276(5321):2045-7.
106. Snead D, Eliezer D. Alpha-synuclein function and dysfunction on cellular membranes. Exp Neurobiol 2014;23(4):292-313.
107. Le W, Sayana P, Jankovic J. Animal models of Parkinson's disease: a gateway to therapeutics? Neurotherapeutics 2014;11(1):92-110.
108. Luk KC, Kehm VM, Zhang B, O'Brien P, Trojanowski JQ, Lee VM. Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med 2012;209(5):975-86.
109. George S, Rey NL, Reichenbach N, Steiner JA, Brundin P. Alpha-synuclein: the long distance runner. Brain Pathol 2013;23(3):350-7.
110. Dawson TM, Dawson VL. The role of parkin in familial and sporadic Parkinson's disease. Mov Disord 2010;25(Suppl. 1):S32-9.
111. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392(6676):605-8.
112. Poorkaj P, Nutt JG, James D, Gancher S, Bird TD, Steinbart E, et al. parkin mutation analysis in clinic patients with early-onset Parkinson [corrected] disease. Am J Med Genet A 2004;129A(1):44-50.
113. Perez FA, Palmiter RD. Parkin-deficient mice are not a robust model of parkinsonism. Proc Natl Acad Sci USA 2005;102(6):2174-9.
114. Lu XH, Fleming SM, Meurers B, Ackerson LC, Mortazavi F, Lo V, et al. Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein. J Neurosci 2009;29(7):1962-76.
115. Lazarou M, Narendra DP, Jin SM, Tekle E, Banerjee S, Youle RJ. PINK1 drives Parkin self-association and HECT-like E3 activity upstream of mitochondrial binding. J Cell Biol 2013;200(2):163-72.
116. Valente EM, bou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004;304(5674):1158-60.
117. Gautier CA, Kitada T, Shen J. Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. Proc Natl Acad Sci USA 2008;105(32):11364-9.
118. Gispert S, Ricciardi F, Kurz A, Azizov M, Hoepken HH, Becker D, et al. Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration. PLoS One 2009;4(6):e5777.
119. Oliveras-Salva M, Macchi F, Coessens V, Deleersnijder A, Gerard M, Van der PA, et al. Alpha-synuclein-induced neurodegeneration is exacerbated in PINK1 knockout mice. Neurobiol Aging 2014;35(11):2625-36.
120. Ariga H, Takahashi-Niki K, Kato I, Maita H, Niki T, Iguchi-Ariga SM. Neuroprotective function of DJ-1 in Parkinson's disease. Oxid Med Cell Longev 2013;2013:683920.
121. Hedrich K, Djarmati A, Schafer N, Hering R, Wellenbrock C, Weiss PH, et al. DJ-1 (PARK7) mutations are less frequent than Parkin (PARK2) mutations in early-onset Parkinson disease. Neurology 2004;62(3):389-94.
122. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003;299(5604):256-9.
123. Goldberg MS, Pisani A, Haburcak M, Vortherms TA, Kitada T, Costa C, et al. Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron 2005;45(4): 489-496.
124. Kim RH, Smith PD, Aleyasin H, Hayley S, Mount MP, Pownall S, et al. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc Natl Acad Sci USA 2005;102(14):5215-20.
125. Pham TT, Giesert F, Rothig A, Floss T, Kallnik M, Weindl K, et al. DJ-1-deficient mice show less TH-positive neurons in the ventral tegmental area and exhibit non-motoric behavioural impairments. Genes Brain Behav 2010;9(3):305-17.
126. Rousseaux MW, Marcogliese PC, Qu D, Hewitt SJ, Seang S, Kim RH, et al. Progressive dopaminergic cell loss with unilateral-to-bilateral progression in a genetic model of Parkinson disease. Proc Natl Acad Sci USA 2012;109(39):15918-23.
127. Smith WW, Pei Z, Jiang H, Moore DJ, Liang Y, West AB, et al. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci USA 2005;102(51): 18676-18681.
128. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004;44(4):601-7.
129. Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008;7(7): 583-590.
130. Gilks WP, bou-Sleiman PM, Gandhi S, Jain S, Singleton A, Lees AJ, et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 2005;365(9457):415-6.
131. Ozelius LJ, Senthil G, Saunders-Pullman R, Ohmann E, Deligtisch A, Tagliati M, et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 2006;354(4):424-5.
132. Hulihan MM, Ishihara-Paul L, Kachergus J, Warren L, Amouri R, Elango R, et al. LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study. Lancet Neurol 2008;7(7):591-4.
133. Rudenko IN, Cookson MR. Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications. Neurotherapeutics 2014;11(4):738-50.
134. Ramonet D, Daher JP, Lin BM, Stafa K, Kim J, Banerjee R, et al. Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One 2011;6(4):e18568.
135. Tong Y, Pisani A, Martella G, Karouani M, Yamaguchi H, Pothos EN, et al. R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc Natl Acad Sci USA 2009;106(34):14622-7.
136. Hinkle KM, Yue M, Behrouz B, Dachsel JC, Lincoln SJ, Bowles EE, et al. LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors. Mol Neurodegener 2012;7:25.
137. Blesa J, Przedborski S. Parkinson's disease: animal models and dopaminergic cell vulnerability. Front Neuroanat 2014;8:155.
138. Li Y, Liu W, Oo TF, Wang L, Tang Y, Jackson-Lewis V, et al. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci 2009;12(7):826-8.
139. Melrose HL, Dachsel JC, Behrouz B, Lincoln SJ, Yue M, Hinkle KM, et al. Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol Dis 2010;40(3):503-17.
140. Dusonchet J, Kochubey O, Stafa K, Young Jr SM, Zufferey R, Moore DJ, et al. A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2. J Neurosci 2011;31(3):907-12.
141. Gonzalez-Reyes LE, Verbitsky M, Blesa J, Jackson-Lewis V, Paredes D, Tillack K, et al. Sonic hedgehog maintains cellular and neurochemical homeostasis in the adult nigrostriatal circuit. Neuron 2012;75(2):306-19.
142. Jankovic J, Chen S, Le WD. The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease. Prog Neurobiol 2005;77(1-2):128-38.
143. Li J, Dani JA, Le W. The role of transcription factor Pitx3 in dopamine neuron development and Parkinson's disease. Curr Top Med Chem 2009;9(10):855-9.
144. Ekstrand MI, Terzioglu M, Galter D, Zhu S, Hofstetter C, Lindqvist E, et al. Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc Natl Acad Sci USA 2007;104(4):1325-30.
145. Assous M, Had-Aissouni L, Gubellini P, Melon C, Nafia I, Salin P, et al. Progressive Parkinsonism by acute dysfunction of excitatory amino acid transporters in the rat substantia nigra. Neurobiol Dis 2014;65:69-81.
146. Kadkhodaei B, Ito T, Joodmardi E, Mattsson B, Rouillard C, Carta M, et al. Nurr1 is required for maintenance of maturing and adult midbrain dopamine neurons. J Neurosci 2009;29(50):15923-32.
147. Hwang DY, Fleming SM, Ardayfio P, Moran-Gates T, Kim H, Tarazi FI, et al. 3,4-dihydroxyphenylalanine reverses the motor deficits in Pitx3-deficient aphakia mice: behavioral characterization of a novel genetic model of Parkinson's disease. J Neurosci 2005;25(8):2132-7.
148. Haubenberger D, Reinthaler E, Mueller JC, Pirker W, Katzenschlager R, Froehlich R, et al. Association of transcription factor polymorphisms PITX3 and EN1 with Parkinson's disease. Neurobiol Aging 2011;32(2):302-7.
149. Nordstrom U, Beauvais G, Ghosh A, Pulikkaparambil Sasidharan BC, Lundblad M, Fuchs J, et al. Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease. Neurobiol Dis 2015;73:70-82.
150. Le PG, Sonnier L, Hartmann A, Bizot JC, Trovero F, Krebs MO, et al. Progressive loss of dopaminergic neurons in the ventral midbrain of adult mice heterozygote for Engrailed1: a new genetic model for Parkinson's disease? Parkinsonism Relat Disord 2008;14(Suppl. 2):S107-11.
151. Falkenberg M, Larsson NG, Gustafsson CM. DNA replication and transcription in mammalian mitochondria. Annu Rev Biochem 2007;76:679-99.
152. Ekstrand MI, Galter D. The MitoPark Mouse-an animal model of Parkinson's disease with impaired respiratory chain function in dopamine neurons. Parkinsonism Relat Disord 2009;15(Suppl. 3):S185-8.
153. Yacoubian TA, Standaert DG. Targets for neuroprotection in Parkinson's disease. Biochim Biophys Acta 2009;1792(7):676-87.
154. Nafia I, Re DB, Masmejean F, Melon C, Kachidian P, Kerkerian-Le GL, et al. Preferential vulnerability of mesencephalic dopamine neurons to glutamate transporter dysfunction. J Neurochem 2008;105(2): 484-496.